| Sponsor | Drug/Program Name | Phase | Indication(s) | Description | Related Compound/Class |
|---|---|---|---|---|---|
| 2A Biosciences | Unnamed | Discovery/Preclinical | Ocular neurodegeneration, undisclosed neuropsychiatric disorders | ||
| Alexander Shulgin Research Institute | ASR-2001 | Discovery/Preclinical | 5-HT2A/2B Agonist | Phenethylamine | |
| Arcadia Medicine | AM-1006 | Discovery/Preclinical | SUDs | "Subperceptual psychoactive drug" | |
| AtaiBeckley | EGX-121 and others | Discovery/Preclinical | OUD & TRD | "non-tryptamine NCE" | |
| BetterLife Pharma | BETR-001 | Discovery/Preclinical | MDD; Anxiety Disorder; Neuropathic Pain | BOL-148 | BOL-148 |
| Bright Minds Biosciences | BMB-201 | Discovery/Preclinical | Depression, Pain, Headache | 5-HT2A/2C Agonist | |
| Ceruvia Lifesciences | NYPRG-101 | Phase I | Migraine; Headache Disorders; Alcohol and Opioid Use Disorder | BOL-148 | LSD/BOL-148 |
| Collaborations Pharmaceuticals | Psychoplastogens | Discovery/Preclinical | OUD | "5HT2A Partial Agonist" and "5HT2C Agonist" | |
| Delix Therapeutics | DLX-001 | Phase I | MDD | Zalsupindole / AAZ-A-154 | 5-MeO-DMT |
| Delix Therapeutics | DLX-007 | Discovery/Preclinical | SUDs | Tabernanthalog | Iboga |
| Delix Therapeutics | Various NCEs | Discovery/Preclinical | |||
| Elkedonia | Various neuroplastogens | Discovery/Preclinical | Undisclosed | ||
| Enveric Biosciences | EB-003 | Discovery/Preclinical | Undisclosed psychiatry | "engages both the 5-HT2A and 5-HT1B receptors" | |
| Equulus Theraeputics | EQL-101 | Discovery/Preclinical | Substance Use Disorders | Non-hallucinogennic ibogaine derivative | Ibogaine / 18-MC derivative |
| Five Discovery | FVE-101 | Discovery/Preclinical | Levodopa-induced duskinesia, Parkinsons disease, TBI | 5-MeO-DMT inspired | 5-MeO-DMT |
| Five Discovery | FVE-102 | Discovery/Preclinical | Alzheimer's Disease | 5-MeO-DMT inspired | 5-MeO-DMT |
| Gilgamesh Pharmaceuticals | GM-5022 | Discovery/Preclinical | "Depression, Anxiety, and Others" | "Oral neuroplastogen" (partnered with AbbVie) | |
| J&J | ITI-1549 | Discovery/Preclinical | Mood and neuropsychiatric disorders | Pyridopyrroloquinoxaline family | |
| Küleon Bioscience | KB-128 | Discovery/Preclinical | Alcohol Use Disorder | 5-HT2C agonist | |
| Marvel Biosciences Corp | Various neuroplastogens | Discovery/Preclinical | "...a set of molecules inspired by the tryptamine class of psychedelics" | Tryptamines | |
| Negev Labs / Parow Entheobiosciences | HBL20017 | Discovery/Preclinical | OCD | ||
| Ocellaris | Various NCEs | Discovery/Preclinical | Neuropsychiatry | ||
| Psilera | PSIL-006 | Discovery/Preclinical | Frontotemporal Dementia | Company's lead candidate | Psilocybin |
| Psilera | PSIL-006 Prodrugs | Discovery/Preclinical | Dementias & AUD | Psilocybin | |
| Psilera | PSIL-025 | Discovery/Preclinical | Anxiety Disorders | Psilocybin | |
| Reunion Neuroscience | RE245 | Discovery/Preclinical | Undisclosed | ||
| Seaport Therapeutics | SPT-348 | Discovery/Preclinical | Headache Disorders; TRD | BOL-148 prodrug | LSD/BOL-148 |
| Tactogen | TACT908 | Discovery/Preclinical | Cluster Headache | 5-HT1B/2A Agonist | DMT |
| Transneural Therapeutics | Exploratory Programs | Discovery/Preclinical | Parkinson's and other neurodegenerative conditions | "Diverse serotonergic programs (e.g., 5-HT2C Agonist) | |
| Transneural Therapeutics | TN-001 | Discovery/Preclinical | MDD; PTSD | Dual 5-HT2A Partial Agonist / 5-HT2B Antagonist Neuroplastogen | |
| Transneural Therapeutics | TN-002 | Discovery/Preclinical | Migraine/Chronic Pain | 5-HT2B Antagonist | |
| Xylo Bio | XYL-1001 | Discovery/Preclinical | Depression | Selective 5-HT2A agonist | |
| Xylo Bio | XYL-200X | Discovery/Preclinical | Anxiety | Multi-target 5-HT2A agonist | |
| Xylo Bio | XYL-300X | Discovery/Preclinical | Undisclosed Neurology | ||
| Xylo Bio | XYL-400X | Discovery/Preclinical | SUDs |
Explore the entire psychedelic pipeline→ View the Psychedelic Drug Development Tracker
Join thousands of psychedelics insiders
Get the weekly psychedelic medicine briefing.
A free weekly digest covering trials, regulation, policy, and access.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.